Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar;91(2):219-28.
doi: 10.1007/s12185-009-0490-3.

Sandwich ELISA for hemoglobin A2 quantification and identification of beta-thalassemia carriers

Affiliations

Sandwich ELISA for hemoglobin A2 quantification and identification of beta-thalassemia carriers

Surakit Kuntaruk et al. Int J Hematol. 2010 Mar.

Abstract

Hemoglobin (Hb) A2 (alpha2delta2) is a minor hemoglobin in human red blood cells. An abnormal increase in the level of HbA2 is the most significant parameter in the diagnosis of beta-thalassemia carriers. In this study, we produced two monoclonal antibodies (mAbs) that specifically react to the delta-globin chain of HbA2. A sandwich type ELISA was developed employing the produced anti-HbA2 mAbs. HbA2 levels quantified by the developed sandwich ELISA were highly correlated with those obtained from the standard HPLC method (r = 0.934, p < 0.001). HbA2 levels determined by the ELISA were 4.4 +/- 1.9% in beta-thalassemia heterozygotes compared to 1.4 +/- 0.8, 1.9 +/- 0.8, 1.5 +/- 0.8 and 1.5 +/- 0.6% in normal subjects, HbE heterozygotes, suspected alpha-thalassemia heterozygotes and HbE homozygotes, respectively. Using a cut-off value of 2.5%, beta-thalassemia heterozygotes could be separated from non-beta-thalassemia heterozygotes with the same accuracy as obtained using the standard HPLC method. More importantly, the developed ELISA was able to determine HbA2 levels in HbE-bearing individuals which could not be done by the HPLC method. Our results suggest that this sandwich ELISA can be applied for mass screening for beta-thalassemia heterozygotes, especially in resource-limited countries, where beta-thalassemia is highly prevalent.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Transl Res. 2008 Oct;152(4):178-84 - PubMed
    1. Int J Hematol. 2006 Jun;83(5):408-14 - PubMed
    1. J Immunoassay Immunochem. 2004;25(2):135-46 - PubMed
    1. Southeast Asian J Trop Med Public Health. 1992 Dec;23(4):647-55 - PubMed
    1. Acta Haematol. 1997;98(4):187-94 - PubMed

Publication types

MeSH terms

LinkOut - more resources